The 2026 Cholesterol Rules Just Added a Test Most Adults Never Had: Lp(a)

Cholesterol advice used to be simple: get your LDL checked, maybe your HDL, and hope for the best. The 2026 ACC/AHA dyslipidemia guideline rewrites that. The headline change is a test most adults have never heard of — Lp(a) — and it can reframe your heart risk overnight.

Key Takeaways

• The 2026 ACC/AHA guideline recommends a one-time Lp(a) test for all adults, a Class 1 recommendation, up from its older "risk enhancer" status (AHA/ACC, 2026).
• It also gives ApoB and hsCRP testing greater weight and replaces the old 10-year risk tool with the PREVENT equation, which adds a 30-year risk view (AHA/ACC, 2026).
• Specific LDL targets return for the first time since 2013: under 70 mg/dL for high-risk and under 55 mg/dL for very-high-risk patients (AHA/ACC, 2026).
• One analysis projects 56.6% of U.S. adults aged 30–79 — about 87.5 million — are now statin-eligible under the new rule (JAMA, 2026).

Why Does the New Guideline Want an Lp(a) Test?

Lp(a), or lipoprotein(a), is a cholesterol particle that is mostly genetic and stays steady through life, so one test is enough. The 2026 guideline upgraded it to a Class 1 recommendation for all adults because high Lp(a) is one of the strongest inherited drivers of heart attack and stroke risk (AHA/ACC, 2026). Some estimates put each Lp(a) particle as far more atherogenic than ordinary LDL. The point is not to treat Lp(a) with a pill yet — it is to reclassify people whose "normal" LDL hid a real inherited risk.

Citation capsule: The 2026 ACC/AHA guideline makes a one-time Lp(a) test a Class 1 recommendation for every adult because elevated Lp(a) is a potent, largely genetic driver of cardiovascular risk that standard LDL testing can miss (AHA/ACC, 2026).

This builds on our cholesterol screening starts at 19 article; Lp(a) is the next layer.

What Else Changed in the 2026 Rule?

Three shifts matter. First, ApoB — a count of all the atherogenic particles, not just LDL — gets more emphasis as a better risk marker than LDL alone (AHA/ACC, 2026). Second, the old Pooled Cohort risk calculator is replaced by PREVENT, which estimates both 10-year and 30-year risk and drops race from the formula (AHA/ACC, 2026). Third, specific LDL targets are back: under 70 mg/dL for high-risk patients and under 55 mg/dL for very-high-risk, the first time numeric goals returned since 2013.

Citation capsule: Alongside Lp(a), the 2026 guideline promotes ApoB testing, swaps the Pooled Cohort equations for PREVENT with a 30-year risk view, and restores specific LDL targets of under 70 and under 55 mg/dL for high- and very-high-risk patients (AHA/ACC, 2026).

Our CKM syndrome guideline article explains why metabolic and kidney risk now travel together with lipids.

Does This Mean Millions More People Need Statins?

Yes, but mostly younger and lower-risk people. A JAMA analysis of the 2026 guideline estimated 56.6% of U.S. adults aged 30–79 — about 87.5 million — are now statin-eligible, including 21.5 million newly eligible, and the new group skews younger with lower 10-year risk (JAMA, 2026). The shift is from "treat only high short-term risk" to "treat the long arc of risk." That is a sea change in counseling, and it is why our statin muscle aches guide matters more, not less.

Citation capsule: Under the 2026 guideline roughly 56.6% of adults aged 30–79 are statin-eligible with 21.5 million newly eligible and a younger, lower short-term-risk profile, reflecting the move to 30-year risk framing (JAMA, 2026).

If you are nervous about starting, our statins feared online article separates myth from evidence.

What Should You Ask Your Clinician?

Ask for a one-time Lp(a) and an ApoB alongside your next lipid panel, and ask which risk window — 10 or 30 years — your plan uses (clinical guidance, 2026). If you already have diabetes, prior heart disease, or CKD, ask whether your LDL target is now under 70 or under 55 mg/dL. These are concrete, billable questions the new guideline was written to answer.

Citation capsule: Patients should request a one-time Lp(a) and ApoB at their next lipid check and confirm their LDL target — under 70 or under 55 mg/dL — based on their risk tier under the 2026 guideline (clinical guidance, 2026).

Pair this with our blood pressure pill not working read if your numbers stay stubborn.

Frequently Asked Questions

Do I need the Lp(a) test every year?

No. Lp(a) is genetically stable, so the 2026 guideline recommends a single lifetime test for all adults (AHA/ACC, 2026).

Is ApoB better than LDL?

ApoB counts all artery-clogging particles and is often a better risk marker than LDL alone, which is why the guideline prioritizes it (AHA/ACC, 2026).

Why did they bring back LDL targets?

The 2026 guideline restored specific targets (under 70 and under 55 mg/dL) for high- and very-high-risk patients, a return to goal-based treatment (AHA/ACC, 2026).

Will my insurance cover more testing?

Coverage varies, but Lp(a) and ApoB are increasingly standard; ask your clinician what your plan allows (clinical guidance, 2026).

Conclusion

The 2026 cholesterol rule turns a once-a-year LDL check into a fuller risk picture: a one-time Lp(a), an ApoB, and a 30-year view of your arteries. The changes will pull millions of younger adults onto statins — not as over-treatment, but as early protection. The single most useful thing you can do is ask for the Lp(a) test most adults have never had.

Sources

• American Heart Association / American College of Cardiology. 2026 Guideline on the Management of Dyslipidemia. Circulation. 2026. Retrieved 2026-08-11. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001423
• Anderson T, et al. Implications of the 2026 Dyslipidemia Guideline for Primary Prevention Statin Therapy. JAMA. 2026;335(2). Retrieved 2026-08-11. https://jamanetwork.com/journals/jama/fullarticle/2851792